HEADER HYDROLASE 07-FEB-06 2FYE TITLE MUTANT HUMAN CATHEPSIN S WITH IRREVERSIBLE INHIBITOR CRA-14013 COMPND MOL_ID: 1; COMPND 2 MOLECULE: CATHEPSIN S PREPROPROTEIN; COMPND 3 CHAIN: A; COMPND 4 EC: 3.4.22.27; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: PICHIA PASTORIS; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 4922 KEYWDS PAPAIN, CYSTEINE PROTEASE, DRUG DESIGN, 14013, HYDROLASE EXPDTA X-RAY DIFFRACTION AUTHOR J.R.SOMOZA REVDAT 4 20-OCT-21 2FYE 1 REMARK SEQADV LINK REVDAT 3 18-OCT-17 2FYE 1 REMARK REVDAT 2 24-FEB-09 2FYE 1 VERSN REVDAT 1 08-AUG-06 2FYE 0 JRNL AUTH J.R.SOMOZA JRNL TITL MUTANT HUMAN CATHEPSIN S WITH IRREVERSIBLE INHIBITOR JRNL TITL 2 CRA-14013 JRNL REF TO BE PUBLISHED JRNL REFN REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 65.70 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 85.5 REMARK 3 NUMBER OF REFLECTIONS : 17532 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.194 REMARK 3 FREE R VALUE : 0.210 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 8.300 REMARK 3 FREE R VALUE TEST SET COUNT : 1705 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 34 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.20 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.22 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 448 REMARK 3 BIN R VALUE (WORKING SET) : 0.3240 REMARK 3 BIN FREE R VALUE : 0.3800 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 43 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1640 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 45 REMARK 3 SOLVENT ATOMS : 78 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 21.93 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 2.05900 REMARK 3 B22 (A**2) : -1.95100 REMARK 3 B33 (A**2) : -0.10800 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.25 REMARK 3 ESD FROM SIGMAA (A) : 0.36 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.29 REMARK 3 ESD FROM C-V SIGMAA (A) : 0.42 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.006 REMARK 3 BOND ANGLES (DEGREES) : 1.100 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : MSI_CNX_TOPPAR:PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : PARHCSDX_FROM_MARY.PRO REMARK 3 PARAMETER FILE 3 : MSI_CNX_TOPPAR:WATER_REP.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2FYE COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-MAR-06. REMARK 100 THE DEPOSITION ID IS D_1000036458. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 25-FEB-00 REMARK 200 TEMPERATURE (KELVIN) : 280.0 REMARK 200 PH : 4.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU RU200 REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 18684 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 100.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 91.3 REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : 0.12400 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 7.6000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.28 REMARK 200 COMPLETENESS FOR SHELL (%) : 94.4 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.63200 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: FOURIER SYNTHESIS REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 70.09 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 4.11 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: UNDER TYPICAL CRYSTALLIZATION REMARK 280 CONDITIONS THE RESERVOIR CONTAINED 80 MM AMMONIUM SULFATE AND 12% REMARK 280 (W/V) POLYETHYLENE GLYCOL 8000. THIS WAS ALLOWED TO EQUILIBRATE REMARK 280 WITH A HANGING DROP CONTAINING 2 MICROLITERS OF THE RESERVOIR REMARK 280 SOLUTION AND 2 MICROLITERS OF A 10 MG/ML PROTEIN SOLUTION IN 25 REMARK 280 MM SODIUM ACETATE (PH 4.5). , VAPOR DIFFUSION, TEMPERATURE 280K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 39.79000 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 42.71500 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 58.13000 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 39.79000 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 42.71500 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 58.13000 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 39.79000 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 42.71500 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 58.13000 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 39.79000 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 42.71500 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 58.13000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE BIOLOGICALLY-RELEVANT UNIT IS PROBABLY THE MONOMER. REMARK 300 THERE IS ONE MONOMER/ASYMMETRIC UNIT. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 9 CG CD OE1 OE2 REMARK 470 LYS A 41 CG CD CE NZ REMARK 470 LYS A 44 CG CD CE NZ REMARK 470 LYS A 57B CG CD CE NZ REMARK 470 LYS A 57C CG CD CE NZ REMARK 470 LYS A 78A CG CD CE NZ REMARK 470 LYS A 89 CG CD CE NZ REMARK 470 LYS A 94 CG CD CE NZ REMARK 470 ARG A 108 CG CD NE CZ NH1 NH2 REMARK 470 HIS A 179 CG ND1 CD2 CE1 NE2 REMARK 470 LYS A 184 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ALA A 24 34.91 -87.57 REMARK 500 THR A 57A -135.97 -107.29 REMARK 500 ASN A 158 -7.23 -151.36 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BCQ A 281 DBREF 2FYE A 1 211 UNP P25774 CATS_HUMAN 115 331 SEQADV 2FYE LYS A 57B UNP P25774 GLU 173 VARIANT SEQADV 2FYE ALA A 100 UNP P25774 LYS 218 VARIANT SEQADV 2FYE ARG A 108 UNP P25774 SER 225 ENGINEERED MUTATION SEQADV 2FYE LYS A 184 UNP P25774 GLU 307 ENGINEERED MUTATION SEQRES 1 A 217 LEU PRO ASP SER VAL ASP TRP ARG GLU LYS GLY CYS VAL SEQRES 2 A 217 THR GLU VAL LYS TYR GLN GLY SER CYS GLY ALA CYS TRP SEQRES 3 A 217 ALA PHE SER ALA VAL GLY ALA LEU GLU ALA GLN LEU LYS SEQRES 4 A 217 LEU LYS THR GLY LYS LEU VAL SER LEU SER ALA GLN ASN SEQRES 5 A 217 LEU VAL ASP CYS SER THR LYS LYS TYR GLY ASN LYS GLY SEQRES 6 A 217 CYS ASN GLY GLY PHE MET THR THR ALA PHE GLN TYR ILE SEQRES 7 A 217 ILE ASP ASN LYS GLY ILE ASP SER ASP ALA SER TYR PRO SEQRES 8 A 217 TYR LYS ALA MET ASP GLN LYS CYS GLN TYR ASP SER ALA SEQRES 9 A 217 TYR ARG ALA ALA THR CYS ARG LYS TYR THR GLU LEU PRO SEQRES 10 A 217 TYR GLY ARG GLU ASP VAL LEU LYS GLU ALA VAL ALA ASN SEQRES 11 A 217 LYS GLY PRO VAL SER VAL GLY VAL ASP ALA ARG HIS PRO SEQRES 12 A 217 SER PHE PHE LEU TYR ARG SER GLY VAL TYR TYR GLU PRO SEQRES 13 A 217 SER CYS THR GLN ASN VAL ASN HIS GLY VAL LEU VAL VAL SEQRES 14 A 217 GLY TYR GLY ASP LEU ASN GLY LYS GLU TYR TRP LEU VAL SEQRES 15 A 217 LYS ASN SER TRP GLY HIS ASN PHE GLY GLU LYS GLY TYR SEQRES 16 A 217 ILE ARG MET ALA ARG ASN LYS GLY ASN HIS CYS GLY ILE SEQRES 17 A 217 ALA SER PHE PRO SER TYR PRO GLU ILE HET BCQ A 281 45 HETNAM BCQ N-[(1R)-1-[({[(5S)-3,5-DIMETHYL-2,5-DIHYDROISOXAZOL-4- HETNAM 2 BCQ YL]METHYL}SULFONYL)METHYL]-2-OXO-2-({(1S)-3-PHENYL-1- HETNAM 3 BCQ [2-(PHENYLSULFONYL)ETHYL]PROPYL}AMINO) HETNAM 4 BCQ ETHYL]MORPHOLINE-4-CARBOXAMIDE FORMUL 2 BCQ C31 H42 N4 O8 S2 FORMUL 3 HOH *78(H2 O) HELIX 1 1 ALA A 24 GLY A 43 1 20 HELIX 2 2 SER A 49 SER A 57 1 9 HELIX 3 3 THR A 57A GLY A 59 5 5 HELIX 4 4 LYS A 61 GLY A 65 5 5 HELIX 5 5 PHE A 67 LYS A 78A 1 13 HELIX 6 6 ASP A 98 ALA A 100 5 3 HELIX 7 7 ARG A 117 LYS A 127A 1 12 HELIX 8 8 HIS A 138 LEU A 143 1 6 HELIX 9 9 ASN A 198 ILE A 202 5 5 SHEET 1 A 3 VAL A 5 ASP A 6 0 SHEET 2 A 3 HIS A 159 LEU A 168A-1 O TYR A 166 N VAL A 5 SHEET 3 A 3 VAL A 130 VAL A 134 -1 N VAL A 132 O VAL A 161 SHEET 1 B 5 VAL A 5 ASP A 6 0 SHEET 2 B 5 HIS A 159 LEU A 168A-1 O TYR A 166 N VAL A 5 SHEET 3 B 5 LYS A 168D LYS A 174 -1 O LEU A 172 N GLY A 165 SHEET 4 B 5 TYR A 186 ALA A 190 -1 O ILE A 187 N VAL A 173 SHEET 5 B 5 VAL A 148 TYR A 149 1 N TYR A 149 O ARG A 188 SHEET 1 C 2 ILE A 80 ASP A 81 0 SHEET 2 C 2 ARG A 102 ALA A 105 -1 O ALA A 103 N ILE A 80 SHEET 1 D 2 LYS A 109 GLU A 112 0 SHEET 2 D 2 SER A 207 GLU A 210 -1 O TYR A 208 N THR A 111 SSBOND 1 CYS A 22 CYS A 63 1555 1555 2.03 SSBOND 2 CYS A 56 CYS A 95 1555 1555 2.03 SSBOND 3 CYS A 153 CYS A 200 1555 1555 2.03 LINK SG CYS A 25 CT BCQ A 281 1555 1555 1.80 SITE 1 AC1 18 GLN A 19 GLY A 23 CYS A 25 TRP A 26 SITE 2 AC1 18 CYS A 63 GLY A 65 GLY A 66 PHE A 67 SITE 3 AC1 18 MET A 68 GLY A 133 ALA A 136 VAL A 157 SITE 4 AC1 18 ASN A 158 HIS A 159 TRP A 177 PHE A 205 SITE 5 AC1 18 HOH A 347 HOH A 356 CRYST1 79.580 85.430 116.260 90.00 90.00 90.00 I 2 2 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012566 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011705 0.000000 0.00000 SCALE3 0.000000 0.000000 0.008601 0.00000